Greentech Group
Unlocking Nature’s Potential for a Healthier World

Microbiota is emerging as the next generation of medicine that exceeds the established benefits offered by allopathy and homeopathy. Numerous scientific journals have documented a correlation between microbiota and metabolic diseases. It takes a true expert to identify and develop a medicinal strain that can work wonders in life-threatening neurodegenerative ailments.

Greentech Group is medicinal biotechnology pioneer with in-depth knowledge of biochemistry and an ability to develop groundbreaking drugs. The company engages in ecological preservation through innovative endeavors ranging from green biotechnology with plants, white biotechnology with microorganisms and blue biotechnology with algae and seaweeds. “We harness nature’s richness to drive innovation across diverse industries, promoting global health and sustainability,” says Jean-Yves Berthon, CEO of Greentech Group.

Its expertise is deeply rooted in understanding biotechnologies and the utilization of natural raw materials essential to its research and development process. Extracting different metabolites from microorganisms and their metabolic products enables Greentech to develop novel ingredients, including transforming substrates into valuable molecules.

The company advances medical solutions while embracing environmental sustainability, showcasing the crucial role of biotechnology in its processes. This promotes the development of sustainable alternatives to existing medicinal biotechnology and drives a more resilient economy through the use of renewable living resources.

Greentech has made significant advancements in identifying microbial strains capable of producing gamma-aminobutyric acid and other molecules to combat chronic pains and neurodegenerative diseases like Alzheimer’s and Parkinson’s through precise research and development.

The company collaborates with pharmaceutical laboratories to commercialize its findings after validating the concept and navigating through the initial two phases of testing. Greentech’s steadfast dedication to sustainability and collaboration is evident in its efforts to bridge the gap between research, production and pharmaceutical partnerships. Another promising discovery is the development of transformed fatty acid extracted from a specific microalgae strain cultivated in a specialized inducing culture medium. This can penetrate the blood-brain barrier for brain disease treatments. The development process involved understanding brain physiology, identifying the scaffold, selecting strain, creating the culture medium and validating the physiological activity.
Beyond healthcare, its expertise encompasses agronomy and environmental conservation, emphasizing the development and use of new biofertilizers, biostimulants and biocontrol products to improve agricultural methods and ensure the preservation of edible water. It also provides new food and feed products derived from algae, plant proteins and probiotics. This showcases its commitment to eco-friendly practices and innovation in the nutrition sector.

A hallmark of Greentech’s operations is its services as a contract development and manufacturing organization. It offers proficiency and production capabilities to partners seeking to develop new products, fostering collaboration and driving progress in the field.

Thorough analysis is conducted for processes like target metabolisms, identification of key enzymes for stimulation or inhibition and use of industrial-scale equipment for large-scale production, along with specialized purification techniques. This serves as a testament to its know-how and meticulous approach to leaving no stone unturned in the pursuit of innovative solutions.

In one instance, a pharmaceutical laboratory contacted Greentech to develop 10-baccatin, a precursor of taxanes used against breast and ovarian tumors. This is naturally produced in the leaves of Taxus but varies with the variety of soil and climatic conditions. Greentech identified taxus plants with high 10-baccatin content and enhanced their production by treating the leaves before harvesting, boosting yield and therapeutic value. Greentech is a good manufacturing practice-certified company with over three decades of industry experience, upholding the highest standards in the pharmaceutical industry. Its influence extends far and wide, with a global presence in France, the U.S., Brazil, Africa, India, Germany, Thailand and Taiwan. By staying true to its values, the company has built trust with its suppliers and customers.

Its team of experts includes chemists, microbiologists, biologists, computational science and artificial intelligence specialists. Their diverse skills enable the team to effectively address complex challenges and achieve successful outcomes in its research and development efforts. The team comprises over 240 collaborators with 50 lab specialists, 18 of whom hold doctorates in different disciplines.

Dedication to harnessing the potential of microbiota and producing high-quality products, coupled with its adherence to advancing scientific knowledge and fostering a healthier, more sustainable world, underscores Greentech’s position as a leading force in the biotechnology industry.